Currently, there are 971.00M common shares owned by the public and among those 943.62M shares have been available to trade.
The company’s stock has a 5-day price change of 3.45% and -22.04% over the past three months. CRM shares are trading -8.82% year to date (YTD), with the 12-month market performance up to 12.49% higher. It has a 12-month low price of $193.68 and touched a high of $318.71 over the same period. CRM has an average intraday trading volume of 7.80 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.38%, -9.20%, and -6.50% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Salesforce Inc (NYSE: CRM) shares accounts for 82.56% of the company’s 971.00M shares outstanding.
It has a market capitalization of $232.50B and a beta (3y monthly) value of 1.28. The stock’s trailing 12-month PE ratio is 43.15, while the earnings-per-share (ttm) stands at $5.56. The company has a PEG of 2.66 and a Quick Ratio of 1.03 with the debt-to-equity ratio at 0.22. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.38% over the week and 3.10% over the month.
Earnings per share for the fiscal year are expected to increase by 20.35%, and 10.99% over the next financial year. EPS should shrink at an annualized rate of 16.24% over the next five years, compared to 24.06% over the past 5-year period.
Looking at the support for the CRM, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on May 30, 2024, with the firm’s price target at $325-$280. Robert W. Baird was of a view on January 11, 2024 that the stock is Outperform, while Morgan Stanley gave the stock Overweight rating on December 21, 2023, issuing a price target of $290- $350. Wells Fargo on their part issued Equal Weight rating on December 20, 2023.
